NCT05770895 Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B Status COMPLETED Phase PHASE1
NCT05765344 Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function Status COMPLETED Phase PHASE1
NCT05760300 A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function Status COMPLETED Phase PHASE1
NCT05729568 A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05718700 Study of Bulevirtide in Participants With Chronic Hepatitis D Infection Status ACTIVE_NOT_RECRUITING Phase N/A
NCT05715528 Study of Obeldesivir in Nonhospitalized Participants With COVID-19 Status COMPLETED Phase PHASE3
NCT05690815 Express Testing and Same-day Initiation of PrEP Study Status ACTIVE_NOT_RECRUITING Phase N/A
NCT05685810 Genetic Determinants of Kidney Disease in People of African Ancestry With HIV Status ACTIVE_NOT_RECRUITING Phase N/A
NCT05676931 Study With Various Immunotherapy Treatments in Participants With Lung Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05675579 A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05650749 GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma Status ENROLLING_BY_INVITATION Phase PHASE1
NCT05633667 Study of Novel Treatment Combinations in Patients With Lung Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05633654 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Status RECRUITING Phase PHASE3
NCT05629208 Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) Status TERMINATED Phase PHASE2
NCT05627466 US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia Status NO_LONGER_AVAILABLE Phase N/A